Technology - Cellular Therapy

EvoCell is developing new platform technologies for autologous cell therapy. These technologies allow adult patient cells (e.g. blood lymphocytes or skin cells) to be reprogrammed to a pluripotent state. Reprogrammed pluripotent cells can subsequently be differentiated into other cell types, such as neurons or beta cells, and serve as a source of target cells to treat degenerative diseases such as Alzheimer’s disease, type 1 diabetes, Parkinson’s disease, spinal cord injuries, and cardiac muscle injury, among others.

Our reprogramming technology will facilitate the customized generation of cells from patients with a multiplicity of needs. Cells from patients carrying genetic mutations will be harvested and subject to reprogramming to a progenitor state. These cells will later be used for testing their response to novel drugs, allowing for a large number of in vitro tests prior to using in patients directly.

Back to Technology